Indian J Sex Transm Dis Indian J Sex Transm Dis
Official Publication of the Indian Association for the Study of Sexually Transmitted Diseases
Indian J Sex Transm Dis
The Journal | Search | Ahead Of Print | Current Issue | Archives | Instructions | Subscribe | Login    Users online: 84   Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size


 
  Table of Contents  
ORIGINAL ARTICLE
Year : 2015  |  Volume : 36  |  Issue : 2  |  Page : 174-177
 

Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases


1 Department of Dermatology and Cosmetic Dermatology, Fortis Hospital, Mumbai, Maharashtra, India
2 Department of Skin-VD, Medical College, Baroda, Gujarat, India

Date of Web Publication12-Oct-2015

Correspondence Address:
Smriti Naswa
Flat No. 111, Surya Apartments, Plot No. 14, Sector-6, Dwarka, New Delhi - 110 075
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7184.167169

Rights and Permissions

 

   Abstract 

Introduction: Vulvar lichen sclerosus (VLS) often remains undetected for years due to lack of awareness, as well as private nature of the disease. Advanced disease severely affects the quality of life and is associated with increased risk of vulvar squamous cell carcinoma (SCC). The aim of this study was to assess the usefulness of a physician-administered clinical scoring system for the clinical diagnosis and evaluation of VLS. To the best of our knowledge, this is the first study using the clinical score developed by Günthert et al. on the VLS patients. Materials and Methods: The study conducted was an observational cross-sectional study of 36 cases attending Dermatology OPD of Government Medical College with clinically proven and previously untreated VLS enrolled over a 1 year period. Cases were retrospectively subjected to evaluation by physician-administered clinical score based on 6 clinical features, viz. erosions, agglutination, hyperkeratosis, stenosis, fissures, and atrophy. Results: The average age of 36 clinically diagnosed VLS cases was 56.4 years. Most common clinical features were hyperkeratosis and atrophy found in 86.11% cases followed by erosions (75%) with one-third cases having grade 2 (severe) changes. One case had well-differentiated SCC clitoris at presentation. The mean physician-administered clinical score was 5.583, and 80.56% cases had clinical score ≥4 validating the clinical diagnosis. Discussion: Early diagnosis and prompt treatment is the key to prevent sequelae and complications of VLS. The physician-administered clinical score can be a useful tool to diagnose and later evaluate the response of treatment and prognosis of VLS cases.


Keywords: Clinical score, vulva, vulvar lichen sclerosus


How to cite this article:
Naswa S, Marfatia YS. Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases. Indian J Sex Transm Dis 2015;36:174-7

How to cite this URL:
Naswa S, Marfatia YS. Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases. Indian J Sex Transm Dis [serial online] 2015 [cited 2023 Nov 28];36:174-7. Available from: https://ijstd.org/text.asp?2015/36/2/174/167169



   Introduction Top


Although the vulva is the most visible female genital structure, it has received the least attention in the medical literature and has even been referred to as "the forgotten pelvic organ." [1] Vulvar lichen sclerosus (VLS) is one of the chronic inflammatory vulvar dermatoses with a prevalence estimated to range from 1 in 300 to 1 in 1000 of all patients referred to dermatology departments. VLS often remains undetected for years. Advanced disease severely affects the quality of life and is associated with increased risk of vulvar squamous cell carcinoma (SCC). [2] The early diagnosis and prompt treatment is of the utmost importance.

Günthert et al. [3] has developed a physician-administered clinical scoring system to validate the diagnosis made clinically and to evaluate treatment response during subsequent follow-ups. This can be an important tool in an otherwise difficult to diagnose condition. The purpose of our study was to assess the usefulness of physician-administered clinical score for the clinical diagnosis and evaluation of VLS in retrospect. To the best of our knowledge, this is the first study using the clinical score developed by Günthert et al. [3] on the VLS patients.


   Materials and methods Top


The study conducted was an observational cross-sectional study. Thirty-six cases attending Dermatology OPD of Government Medical College with clinically proven and previously untreated VLS were enrolled over a 1 year period. The clinical diagnosis was made in presence of following points: [4]

  • Chronic intractable itching over vulva
  • Pigmentary changes (depigmentation) of cutaneous/mucocutaneous aspect of vulva with or without presence of erythema/erosions and fissuring
  • Atrophic changes including labia minora fusion and clitoral atrophy (leading to burying of clitoris with/without introital narrowing).


Biopsy was done in doubtful cases.

Cases were retrospectively subjected to physician-administered clinical score developed by Günthert et al. [3] to validate the diagnosis. The clinical score was evaluated based on clinical findings and photographs of patients.

The clinical score was based on six clinical features: Erosions, agglutination, hyperkeratosis, stenosis, fissures, and atrophy. Each feature was graded on a 3-point Likert scale with grade 0 as normal findings, 1-moderate, and 2-severe changes [Table 1]. [3] Total score of ≥4 (range: 0-12) was considered VLS in the presence of typical symptoms. [3] Typical symptoms pointing toward diagnosis besides intractable itching and/or soreness were irritation, dyspareunia, dysuria, and fecal/urinary incontinence.
Table 1: Definition of clinical scores and their grades (0, 1, and 2)

Click here to view



   Results Top


Of 36 clinically diagnosed VLS cases, 31 (86%) were post-menopausal while 5 (14%) were in menstruating age group. Average age of the case series was 56.4 years. Most common symptom was intractable itching found in 36 (100%) cases followed by dysuria in 7 (19.4%) cases, dyspareunia in 2 (5.6%) cases, and soreness and urinary incontinence in 1 (2.8%) case each.

The presence and severity of each of the six clinical features were assessed [Table 2]. Most common features were hyperkeratosis and atrophy found in 86.11% cases with at least one-third cases having grade 2 (severe changes). Erosions were seen in 75% cases corresponding with intractable itching, found as the most common presenting symptom [Figure 1]. One case had well-differentiated SCC clitoris at presentation.
Figure 1: A 65-year-old patient with vulvar lichen sclerosus score 9 showing grade 2 erosions, grade 2 hyperkeratosis, grade 2 fissures, grade 1 agglutination, grade 1 atrophy, and grade 1 stenosis

Click here to view
Table 2: Physician-administered clinical score (n=36)

Click here to view


Comparison between present study (n = 36) and study by Günthert et al. [3] (n = 24) revealed that atrophy, hyperkeratosis, and erosion were three most common clinical signs at presentation in both of them [Figure 2] and [Table 3].
Figure 2: A 50-year-old patient with vulvar lichen sclerosus score 4 showing grade 1 erosions, grade 1 hyperkeratosis, grade 1 fissures, and grade 1 atrophy

Click here to view
Table 3: Comparison of clinical signs at presentation in two studies

Click here to view


The mean physician-administered clinical score in the present study was 5.583 (5.5 in Günthert et al. [3] ). Out of 36 patients, 29 had clinical score ≥4; thus validating the clinical diagnosis in 80.56% cases [Figure 3].
Figure 3: Clinical scores of present study (n = 36; range of clinical scores 0– 12; clinical score validating diagnosis of vulvar lichen sclerosus ≥4)

Click here to view



   Discussion Top


VLS is a chronic inflammatory (lymphocyte-mediated) vulvar dermatosis characterized by ivory-white plaques, "cigarette paper" such as epidermal atrophy. [5] There is often a delay in diagnosis of VLS with causes including lack of awareness in patients as well as physicians, failure to examine genital skin properly, and embarrassment to patients due to private nature of the disease. This delay not only affects the quality of life but may also lead to sexual dysfunction and avoidance of sexual intimacy. [1]

VLS has two peak ages of presentation, prepubertal girls and postmenopausal women (mean age of onset is fifth or sixth decades), but is most commonly present in peri- or post-menopausal women. [2],[6] In the present study, there were no prepubertal girls with 86% cases being menopausal.

Women complain of intractable pruritus (worse at night), irritation, soreness, dyspareunia, dysuria, and urinary or fecal incontinence. Nine percent of cases may be asymptomatic. [6] Recalcitrant cases, especially those associated with erosion or progressive scarring may result in severe sexual dysfunction. [5] Intractable pruritus was found in all patients of the present study. In a study by Singh et al., [7] 24 (92.6%) out of 26 VLS patients had intractable itching, 2 (7.7%) had dyspareunia, and 1 (3.8%) had burning micturition. The dyspareunia and problems related to sex are under-reported in Indian studies due to sociocultural taboo in discussing such private issues.

VLS is associated with a 4-6% risk of SCC, making long-term follow-up essential in these patients [2] (level of evidence - C [8] ). In the present study, one patient at the time of presentation had well-defined SCC clitoris associated with VLS highlighting the delayed diagnosis [Figure 4].

Other sequelae/complications include scarring, introital narrowing (stenosis), pseudocyst of the clitoris, sensory abnormalities (dysesthesia, vestibulodynia, and vulvodynia) and psychosexual problems. [4] Intriguingly, the present study had 63.89% cases presenting with stenosis and 86.11% cases with atrophy (commonest presentation along with hyperkeratosis) highlighting that the sequelae/complications were already set in during presentation [Figure 5].
Figure 4: A 70-year-old patient with vulvar lichen sclerosus score 9 showing grade 1 erosions, grade 2 hyperkeratosis, grade 2 agglutination, grade 2 atrophy, and grade 2 stenosis, with well-differentiated squamous cell carcinoma clitoris

Click here to view
Figure 5: A 75-year-old patient with vulvar lichen sclerosus score 11 showing grade 2 erosions, grade 2 hyperkeratosis, grade 1 fissures, grade 2 agglutination, grade 2 atrophy, and grade 2 stenosis

Click here to view


The physician-administered clinical score ≥4 was found in 80.56% cases emphasizing that this clinical score indeed helps in validating diagnosis of VLS with clinical confidence. Remaining 20% cases had typical symptoms, so must be followed periodically (or confirmed with biopsy).

The proper and timely usage of clinical score helps in early diagnosis and prompt treatment of the disease. This early diagnosis and treatment in turn helps alleviate symptoms, prevent architectural damage, and reverse histologic changes.

Advantages of clinical scoring

  • The validation of clinical diagnosis can help in cases refusing biopsy
  • Ensures early diagnosis and prompt treatment of LS which helps prevent the irreversible changes to ensue
  • Good for estimating severity and progression of the disease
  • Good tool to assess treatment response.


Limitations of clinical score

  • Clinical score in the presence of typical symptoms is not sufficient to replace confirmation of VLS by histopathology, so biopsy is still mandatory in doubtful cases.


Take home message

  • VLS is not only chronic but also affects the quality of life including sexual health and has a potential for developing into vulvar malignancy
  • The disease remains under-diagnosed because of lack of awareness on patient's and physician's sides
  • Clinical scoring of vulva is a handy tool to diagnose and later evaluate the progression of the disease
  • Early diagnosis and initiation of treatment to prevent irreversible sequelae holds the center-stage in VLS management.


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Burrows LJ, Shaw HA, Goldstein AT. The vulvar dermatoses. J Sex Med 2008;5:276-83.  Back to cited text no. 1
    
2.
Funaro D. Lichen sclerosus: A review and practical approach. Dermatol Ther 2004;17:28-37.  Back to cited text no. 2
    
3.
Günthert AR, Duclos K, Jahns BG, Krause E, Amann E, Limacher A, et al. Clinical scoring system for vulvar lichen sclerosus. J Sex Med 2012;9:2342-50.  Back to cited text no. 3
    
4.
Neill SM, Tatnall FM, Cox NH. British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002;147:640-9.  Back to cited text no. 4
    
5.
Meffert J.  Lichen Sclerosus et Atrophicus. Available from: . [Last updated on 2015 Mar 20; Last cited on 2015 May 01].  Back to cited text no. 5
    
6.
Singh N, Thappa DM, Jaisankar TJ, Habeebullah S. A clinical study of vulval lichen sclerosus at a tertiary care hospital in South India. Indian J Sex Transm Dis 2007;28:87-90.  Back to cited text no. 6
  Medknow Journal  
7.
Singh N, Thappa DM, Jaisankar TJ, Habeebullah S. Pattern of non-venereal dermatoses of female external genitalia in South India. Dermatol Online J 2008;14:1.  Back to cited text no. 7
    
8.
O′Connell TX, Nathan LS, Satmary WA, Goldstein AT Non-neoplastic epithelial disorders of the vulva. Am Fam Physician 2008;77:321-6.  Back to cited text no. 8
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]


This article has been cited by
1 Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosus: study protocol of a randomized controlled trial
Volker Viereck, Marianne Gamper, Sigrid Regauer, Claudia Walser, Irena Zivanovic
Archives of Gynecology and Obstetrics. 2023;
[Pubmed] | [DOI]
2 Lichen sclerosus: The 2023 update
David A. De Luca, Cristian Papara, Artem Vorobyev, Hernán Staiger, Katja Bieber, Diamant Thaçi, Ralf J. Ludwig
Frontiers in Medicine. 2023; 10
[Pubmed] | [DOI]
3 Laser Therapy for Vulvar Lichen Sclerosus, a Systematic Review
Ana Gil-Villalba, Angela Ayen-Rodriguez, Maria Jose Naranjo-Diaz, Ricardo Ruiz-Villaverde
Life. 2023; 13(11): 2146
[Pubmed] | [DOI]
4 Risk of Development of Vulvar Cancer in Women With Lichen Sclerosus or Lichen Planus: A Systematic Review
Pedro Vieira-Baptista, Faustino R. Pérez-López, María T. López-Baena, Colleen K. Stockdale, Mario Preti, Jacob Bornstein
Journal of Lower Genital Tract Disease. 2022; 26(3): 250
[Pubmed] | [DOI]
5 Development and Validation of a Clinical Grading Scale to Assess the Vulvar Region: The Vulvar Architecture Severity Scale
Aurora Almadori, Nicole Zenner, Deborah Boyle, Victoria Swale, Wendy Reid, Allan Maclean, Peter E M Butler
Aesthetic Surgery Journal. 2020; 40(12): 1319
[Pubmed] | [DOI]
6 Dyspareunia in vulvar lichen sclerosus: an overview of a distressing symptom
Monica Corazza, Annarosa Virgili, Sara Minghetti, Alessandro Borghi
Giornale Italiano di Dermatologia e Venereologia. 2020; 155(3)
[Pubmed] | [DOI]
7 Vulvar lichen sclerosus: A single-center retrospective study in China
Min Yang, Wei Wen, Jianmin Chang
The Journal of Dermatology. 2018; 45(9): 1101
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 

    

 
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (1,431 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and me...
   Results
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed3653    
    Printed140    
    Emailed0    
    PDF Downloaded75    
    Comments [Add]    
    Cited by others 7    

Recommend this journal